- Litigation Briefing: HP&M Issues Report Summarizing Leading Cases and Settlements of 2017 January 8, 2018
- Happy New Year! Lasso Yourself Some FDA Data with the Agency’s New Data Dashboard January 7, 2018
- Up in Smoke? Will the Feds Ramp Up Enforcement Action Against Budding State Marijuana Industry? January 4, 2018
- Continued Interest in Drug Categorization – OIG Finds Ten Potentially Misclassified Drugs May Have Led to $1.3 Billion in Lost Medicaid Rebates January 4, 2018
- FDA Issues Final Guidance on Additive Manufactured (“3D-Printed”) Devices January 3, 2018
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- Patent Baristas
- Patent Docs
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (DDMAC)
- Advertising and Promotion (Federal Trade Commission)
- Animal Drugs and Feeds
- Biosimilars
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
Litigation Briefing: HP&M Issues Report Summarizing Leading Cases and Settlements of 2017
January 8, 2018By Anne K. Walsh & Andrew J. Hull —Hyman, Phelps & McNamara, P.C. is pleased to present this report summarizing leading cases and settlements from 2017 affecting the FDA-regulated industry. Our goal was to provide a concise summary of issues that most impact our clients, many of whom are drug and medical device manufacturers, compounding facilities, and officers of those companies.
For each case or settlement, we summarize the facts and the key takeaways. And we include at the end of the report the hot-button issues that we are monitoring in 2018.
We hope this report proves useful and interesting to you.
Search FDA Law Blog
Subscribe
Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - TOP Rated
Chambers USA
- Litigation Briefing: HP&M Issues Report Summarizing Leading Cases and Settlements of 2017 January 8, 2018
- Happy New Year! Lasso Yourself Some FDA Data with the Agency’s New Data Dashboard January 7, 2018
- Up in Smoke? Will the Feds Ramp Up Enforcement Action Against Budding State Marijuana Industry? January 4, 2018
- Continued Interest in Drug Categorization – OIG Finds Ten Potentially Misclassified Drugs May Have Led to $1.3 Billion in Lost Medicaid Rebates January 4, 2018
- FDA Issues Final Guidance on Additive Manufactured (“3D-Printed”) Devices January 3, 2018
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- Patent Baristas
- Patent Docs
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (DDMAC)
- Advertising and Promotion (Federal Trade Commission)
- Animal Drugs and Feeds
- Biosimilars
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized